Skip to main content

Day: December 5, 2022

At CAGR of 2.9%, Aircraft Tires Market Size is Anticipated to Gain USD 1.6 Bn by 2027

Chicago, Dec. 05, 2022 (GLOBE NEWSWIRE) — Aircraft Tires Market by Type (Radial-ply and Bias-ply), Aircraft Type (Business and General Aviation, Commercial Aviation, Military Aviation), Platform (Fixed-wing and Rotary-wing aircraft), Position, End-User, and Region – Global Forecast to 2027″, Aerospace Manufacturers are developing enhanced Aircraft Tires that are fuel-efficient and durable. There is the adoption of sustainable Aircraft Tires systems, which are environment friendly and have reduced carbon emissions while providing an optimal tread life. Ask for PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163712012 Aircraft Tires Market Report Scope:Report Metric DetailsMarket Size Value in 2022 USD 1.4 BillionRevenue Forecast in 2027 USD 1.6 BillionGrowth Rate 2.9%...

Continue reading

Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta

Special dividend estimated to be in range of $1.34 to $1.43 per share Payment of special dividend conditioned upon closing of both Asset Sale and Merger, which are subject to stockholder approval BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) — Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX) announced today that its Board of Directors has declared a special dividend in connection with the previously announced asset sale to Janssen Pharmaceutica NV (“Janssen”) and merger with Kineta, Inc. (“Kineta”). The special dividend, which the Company estimates will be in range of $1.34 to $1.43 per share of Yumanity common stock, will be payable in cash on or before December 29, 2022, to stockholders of record at the close of business on December 15, 2022. The special dividend will be equal to the gross proceeds of the asset...

Continue reading

Gelatin Market to Hit USD 4.42 Billion by 2029 | At a CAGR of 6.43 %

Companies covered in gelatin market are Gelita AG (Germany), Darling Ingredients Inc. (U.S.), Nitta Gelatin, Inc. (Japan), Tessenderlo Group (Belgium), Weishardt (France), Trobas Gelatine B.V. (Netherlands), Lapi Gelatine S.p.a. (Italy), Juncà Gelatines SL (Spain), Italgel S.r.l (Italy), Sterling Biotech Ltd. (India), Gelnex (Brazil) & more. Pune, India, Dec. 05, 2022 (GLOBE NEWSWIRE) — The global gelatin market size was valued at USD 2.65 billion in 2021. The market is projected to grow from USD 2.86 billion in 2022 to USD 4.42 billion by 2029, exhibiting a CAGR of 6.43% during the forecast period. This information is provided by Fortune Business Insights, in its report titled, “Gelatin Market, 2022-2029.” Get a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/gelatin-market-107012 List...

Continue reading

Aircraft Hangar Market to Worth USD 1,000.6 Million by 2029 | Fortune Business Insights™

According to Fortune Business Insights™, the global aircraft hangar market size is projected to reach USD 1,000.6 Million by 2029, at CAGR of 4.81% during forecast period 2022-2029 Pune, India, Dec. 05, 2022 (GLOBE NEWSWIRE) — The global aircraft hangar market size stood at USD 703.0 million in 2021. The market value is slated to rise from USD 720.3 million in 2022 to USD 1,000.6 million by 2029 at a CAGR of 4.81% during 2022-2029. Hangars can be either fixed or moveable in construction. As they are simple to install, take less time to set up, and are less expensive, inflatable portable hangars are becoming more and more popular. Fortune Business Insights™ presents this information in its report titled, “Global Aircraft Hangar Market, 2022-2028”. Get a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/aircraft-hangar-market-103514 List...

Continue reading

AnPac Announces Strategic Initiative to Establish A Wholly-Owned Subsidiary for US Food Market

PHILADELPHIA, Dec. 05, 2022 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, today announced that the Company has formed a wholly-owned subsidiary Fresh2 Technology Inc in the State of Delaware on October 4, 2022 in order to establish the company’s new product line of business-to-business food trade and delivery platform for local restaurants and supermarkets, a combination of the China’s food distribution strategies and North America’s growing Asian food market. Mr. Haohan Xu, the Co-CEO commented: “We are dedicated to developing and producing high-performance platform and supply chain of food distribution system, for a broader client group in US local...

Continue reading

Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical

The Sudan Ebola and Marburg mAb programs were awarded approximately $190 million of BARDA funding covering manufacturing, efficacy and safety evaluations, and regulatory approvalLos Gatos, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, signed an exclusive term sheet to secure international development and global commercial rights upon licensure for the pan-Ebola and pan-Marburg monoclonal antibody (mAbs) programs from Mapp Biopharmaceutical, Inc. (MappBio), a privately-owned leading developer of novel pharmaceuticals for the prevention and treatment of infectious diseases with a focus on unmet needs in global health and biodefense.Aridis and...

Continue reading

The Centers for Medicare & Medicaid Services Makes Preliminary Recommendation to Establish New HCPCS Billing Code Dedicated to Arch Therapeutics’ AC5® Advanced Wound System

A dedicated code would represent a key milestone for commercialization of AC5 Advanced Wound System in doctors’ offices and other outpatient settings FRAMINGHAM, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Centers for Medicare and Medicaid Services (“CMS”) has made a preliminary recommendation to establish a dedicated Healthcare Common Procedure Coding System (“HCPCS”) Level II billing code specific to AC5® Advanced Wound System (“AC5”). The preliminary recommendation was discussed at CMS’ First Biannual 2022 HCPCS Public Meeting, which was held on November 30, 2022. The HCPCS code would better enable providers to bill third party payors for AC5 that is used...

Continue reading

Selection of candidates for independent Audit Committee member and Remuneration and Nomination Committee member of AB Klaipėdos nafta is announced

On 5th August, 2022, AB Klaipėdos nafta (hereinafter – the Company), announced a selection of candidates for independent members of the Audit Committee and Remuneration and Nomination Committee under Supervisory Council (hereinafter – Committees) of the Company. The selection is announced for one independent member of the Audit Committee of the Company and for one independent member of the Remuneration and Nomination Committee of the Company. The selection shall be performed according to the Schedule for the selection of independent members of the Audit Committee and Remuneration and Nomination Committee of AB Klaipėdos nafta, approved by the 24th November, 2022 decision of the Supervisory Council of the Company. After the selection procedures are performed, the members of the Committees shall be elected by the Supervisory Council of the...

Continue reading

Form 8.3 – [Devro plc – 02 12 2022] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree DEVRO PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Lilium expands into UK market with eVolare, signs binding contract including pre-delivery payment for up to 20 aircraft

Lilium expands into UK market with eVolare and the Lilium Pioneer Edition The Lilium Pioneer Edition, which formally launches today, is a 50 aircraft limited-edition exclusive version of the Lilium Jet. Find out more: Link to press release #Lilium #eVTOLeVolare secures deliveries of ten Lilium Pioneer Edition Jets with an option to reserve up to an additional ten Lilium Pioneer Edition Jets   eVolare to serve the Greater London area from its Oxford base eVolare to pay pre-delivery payment to Lilium to secure aircraft delivery slots The order coincides with the formal launch of the Lilium Pioneer Edition, a 50 aircraft limited-edition exclusive version of the Lilium JetOXFORD, United Kingdom and MUNICH, Germany, Dec. 05, 2022 (GLOBE NEWSWIRE) — Lilium N.V. (NASDAQ: LILM), developer of the first all-electric vertical take-off...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.